HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Infectious Disease
Sys. Review
Narrative review offers theoretical guidance for early prevention, treatment, and prognosis of hepatocellular carcinoma.
New Framework Reveals How Inflammation Fuels Liver Cancer
This narrative review provides systematic theoretical guidance for early prevention, precise treatment, and prognosis improvement of hepatoc…
Understanding inflammation helps doctors stop liver cancer before it spreads.
Frontiers
Apr 23, 2026
Radiology & Imaging
Cohort
TACE plus donafenib and camrelizumab shows improved outcomes in unresectable hepatocellular carcinoma
Liver Cancer Patients May Live Twice as Long With New Combo
This single-center retrospective cohort study compared TACE plus donafenib and camrelizumab to TACE plus donafenib alone in 116 patients wit…
A new combination therapy could nearly double survival time for advanced liver cancer patients.
Frontiers
Apr 23, 2026
Oncology
Guideline
Expert consensus guideline on TACE for unresectable HCC in Vietnam
Vietnam Unveils New Rules for Liver Cancer Treatment
This expert consensus guideline addresses transarterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma in …
Vietnam’s medical leaders have created a clear plan to improve liver cancer care.
Frontiers
Apr 23, 2026
Infectious Disease
Sys. Review
Integrative review of Epimedium flavonoids in hepatitis and cirrhosis shows preclinical promise but lacks clinical validation.
Ancient Herb Shows New Promise for Liver Scarring and Hepatitis
This integrative review synthesizes data from 33 high-impact studies regarding Epimedium species and its bioactive flavonoids, icariin and i…
This research suggests a traditional herb may offer a new way to protect the liver, but more work is needed to prove it’s safe and effective…
Frontiers
Apr 22, 2026
Allergy & Immunology
Cohort
Pilot study reports 60.0% conversion rate with lenvatinib, envafolimab, and TACE in hepatocellular carcinoma.
New Liver Cancer Combo Makes Surgery Possible for More Patients
This prospective pilot study enrolled 15 patients with Barcelona Clinic Liver Cancer stage B or C unresectable hepatocellular carcinoma. The…
This new treatment plan turns advanced liver cancer into operable disease for many patients.
Frontiers
Apr 22, 2026
Drug Pipeline
RCT
Huaier granules combined with conventional therapy may improve survival in hepatocellular carcinoma
Does adding Huaier granules help liver cancer patients live longer when combined with standard treatment?
This systematic review of 4,832 patients found that Huaier granules combined with conventional cancer therapy was associated with improved o…
Adding Huaier granules to standard liver cancer treatment helped patients live longer and slowed disease growth compared to therapy alone.
Frontiers
Apr 19, 2026
Oncology
Meta-analysis
Meta-analysis links rare APOB variants to advanced MASLD, cirrhosis, and hepatocellular carcinoma across large cohorts
Do rare gene changes linked to liver disease also raise your risk for cancer and scarring?
This meta-analysis reviews data from the Million Veteran Program, UK Biobank, and clinical cohorts to assess rare APOB variant carriage in p…
Rare gene changes linked to fatty liver disease also raise your risk for liver cancer and severe scarring, according to new findings.
Apr 16, 2026
Allergy & Immunology
Sys. Review
Systematic review examines immunotherapy resistance mechanisms and strategies in hepatocellular carcinoma patients.
Why Liver Cancer Stops Responding to Immunotherapy — and What Could Change That
This systematic review evaluated drug resistance mechanisms and strategies to overcome resistance in patients with hepatocellular carcinoma …
Understanding why liver cancer learns to dodge the immune system's attack is the first step toward treatments that can keep working long-ter…
Frontiers
Apr 16, 2026
Allergy & Immunology
Sys. Review
Review discusses ACSL4 metabolic switch potential in hepatocellular carcinoma therapy strategies
Review suggests metabolic switch concept may guide future liver cancer treatments
This mini-review examines the role of ACSL4 as a metabolic switch rather than a static oncogenic factor in hepatocellular carcinoma. The aut…
Viewing a liver cancer protein as a metabolic switch could guide new therapies that boost a specific cell death process to fight tumors.
Frontiers
Apr 15, 2026
Nutrition & Obesity Medicine
Sys. Review
Review of bile acid homeostasis regulation in liver disease and cancer
Review of bile acid regulation for liver disease conditions shows limited evidence
This narrative review examines the regulation of bile acids homeostasis in conditions including cholestasis, hepatic fibrosis, cirrhosis, he…
Bile acid imbalance drives liver disease, but this review found no data proving that regulating it safely treats conditions like cirrhosis o…
Frontiers
Apr 15, 2026
Gastroenterology
Meta-analysis
Immune Checkpoint Inhibitors Improve Survival and Response Rates in Patients with Hepatocellular Carcinoma Compared to Standard Therapy
New Drug Gives Liver Cancer Patients More Time
This systematic review and meta-analysis evaluated immune checkpoint inhibitors (ICIs) versus standard therapy or placebo in patients with h…
A new drug helps the immune system fight liver cancer, giving patients more time and better survival rates compared to standard treatments.
Apr 14, 2026
Gastroenterology
Meta-analysis
Surgical resection improves survival and reduces recurrence compared to radiofrequency ablation for small hepatocellular carcinoma
Needle or Knife for the Smallest Liver Cancers?
This systematic review and meta-analysis evaluated 3,551 patients with single hepatocellular carcinoma (HCC) ≤ 2 cm comparing surgical resec…
For very small liver cancers, a new review of 14 studies suggests surgery may give better long-term survival than needle ablation, though th…
Apr 14, 2026